We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 148.53 | 0 | 01:00:00 |
From Apr 2021 to Apr 2024
By Chris Wack
F-star Therapeutics Ltd. shares were up 9% to $6.96 in premarket trading Wednesday after the biopharmaceutical company said it entered into a license and collaboration agreement with Johnson & Johnson's Janssen Biotech Inc.
Under the terms of the agreement, F-star said it will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star's proprietary Fcab and mAb platforms.
Janssen will be responsible for all research, development, and commercialization activities under the agreement.
F-star said it is entitled to receive upfront fees of $17.5 million, and near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 20, 2021 08:43 ET (12:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
